Visual and Patient-Reported Outcomes of a Bilaterally Implanted Enhanced Monofocal IOL: A Prospective, Multicenter Study.

Authors

I Paul Singh, Michael Patterson, Zaina Al-Mohtaseb, Brandon D Ayres, George Lau, Farrell Tyson, Ravi Patel, Ehsan Sadri, Eric Donnenfeld

Published in

Journal of cataract and refractive surgery. Oct 27, 2026. Epub Oct 27, 2026.

Abstract

To evaluate the real-world visual and patient-reported outcomes of partial-depth-of-field enhanced monofocal IOL bilaterally implanted in cataract patients targeted for emmetropia.
57 US clinical sites.
Prospective, multicenter, single-arm study.
This study included 338 subjects (651 eyes) who desired cataract surgery and implantation of an enVista Aspire IOL to achieve bilateral emmetropia.
The mean MRSE was -0.18 ± 0.37 D; 85% (551/648) of eyes were within ±0.50 D. The mean binocular UDVA and CDVA were 0.02±0.10 and -0.03±0.07 logMAR, respectively, with 96.5% (299/310) and 99.7% (309/310) of subjects achieving binocular UDVA and CDVA of 20/32 or better. Mean binocular UIVA was 0.20±0.15 logMAR, with 70.9% (219/309) of subjects achieving UIVA of 20/32 or better. Vision at far and intermediate distances without corrective devices was rated as pretty to perfectly well by 92.6% (286/309) of subjects, and 89.6% (277/309) of subjects were satisfied with their postoperative vision. The frequency and bothersomeness of visual symptoms were low (90% or higher proportion of subjects reported visual symptoms occurring "never" to "sometimes"), and almost 90% or higher reported being "not at all" or "only a little" bothered by them. With NAVQ, 52.1% to 71.8% of subjects reported "no or a little difficulty" in doing intermediate to near vision tasks.
Bilateral implantation of enVista Aspire partial-depth-of-field enhanced monofocal IOL demonstrated very good uncorrected visual acuity at far and intermediate and can be a good option for patients who prioritize good distance and intermediate vision and a favorable dysphotopsia profile.

PMID:
42949788
Bibliographic data and abstract were imported from PubMed on 29 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.